KR20230018394A - 조작된 코로나바이러스 스파이크(들) 단백질 및 이의 사용 방법 - Google Patents

조작된 코로나바이러스 스파이크(들) 단백질 및 이의 사용 방법 Download PDF

Info

Publication number
KR20230018394A
KR20230018394A KR1020227042842A KR20227042842A KR20230018394A KR 20230018394 A KR20230018394 A KR 20230018394A KR 1020227042842 A KR1020227042842 A KR 1020227042842A KR 20227042842 A KR20227042842 A KR 20227042842A KR 20230018394 A KR20230018394 A KR 20230018394A
Authority
KR
South Korea
Prior art keywords
engineered
protein
substitution
engineered protein
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227042842A
Other languages
English (en)
Korean (ko)
Inventor
제이슨 맥렐란
제니퍼 메이너드
안드레아 체이스
일리야 핀켈스타인
모함마드 자반마르디
제프리 샤우브
헝-체 쿠오
치아-웨이 초우
조리 골드스미스
크리스티 요르트
칭-린 셰이
패트릭 바이른
니콜 존슨
니안슈앙 왕
다니엘 래프
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
더 트러스티즈 오브 다트마우스 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템, 더 트러스티즈 오브 다트마우스 칼리지 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20230018394A publication Critical patent/KR20230018394A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227042842A 2020-05-29 2021-05-28 조작된 코로나바이러스 스파이크(들) 단백질 및 이의 사용 방법 Pending KR20230018394A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032502P 2020-05-29 2020-05-29
US63/032,502 2020-05-29
PCT/US2021/034713 WO2021243122A2 (en) 2020-05-29 2021-05-28 Engineered coronavirus spike (s) protein and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20230018394A true KR20230018394A (ko) 2023-02-07

Family

ID=78722816

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227042842A Pending KR20230018394A (ko) 2020-05-29 2021-05-28 조작된 코로나바이러스 스파이크(들) 단백질 및 이의 사용 방법

Country Status (10)

Country Link
EP (1) EP4157345A4 (https=)
JP (1) JP2023527556A (https=)
KR (1) KR20230018394A (https=)
CN (1) CN116802193A (https=)
AU (1) AU2021279079A1 (https=)
BR (1) BR112022023591A2 (https=)
CA (1) CA3180554A1 (https=)
IL (1) IL298131A (https=)
MX (1) MX2022015040A (https=)
WO (1) WO2021243122A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012323782B2 (en) 2011-10-12 2017-04-06 Vaxxas Pty Limited Delivery device
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2023067193A2 (en) 2021-10-22 2023-04-27 BioNTech SE Compositions for administration of different doses of rna
US20250122546A1 (en) 2021-10-28 2025-04-17 BioNTech SE Rna constructs and uses thereof
AU2022398292A1 (en) 2021-11-29 2024-06-13 BioNTech SE Coronavirus vaccine
WO2023147091A1 (en) 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
WO2023196634A2 (en) * 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
EP4670167A1 (en) 2023-02-24 2025-12-31 BioNTech SE Systems and methods for modifying synthetic antigens to promote personalized immune responses
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
WO2024243641A1 (en) * 2023-06-02 2024-12-05 Vaxxas Pty Limited Covid vaccine delivered by hd-map
WO2024249848A2 (en) * 2023-06-02 2024-12-05 The Scripps Research Institute Coronavirus s2 immunogens
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
WO2025179238A2 (en) 2024-02-23 2025-08-28 BioNTech SE Coronavirus vaccine
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970398B1 (en) * 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US10538557B2 (en) * 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
US11890339B2 (en) * 2018-08-03 2024-02-06 The United States of Americam as represented by the Secretary, Department of Health and Human Services Nipah virus immunogens and their use
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗

Also Published As

Publication number Publication date
JP2023527556A (ja) 2023-06-29
IL298131A (en) 2023-01-01
AU2021279079A1 (en) 2022-12-15
CN116802193A (zh) 2023-09-22
EP4157345A2 (en) 2023-04-05
CA3180554A1 (en) 2021-12-02
WO2021243122A3 (en) 2022-02-10
WO2021243122A2 (en) 2021-12-02
EP4157345A4 (en) 2024-09-11
US20230242594A1 (en) 2023-08-03
BR112022023591A2 (pt) 2022-12-27
MX2022015040A (es) 2023-02-27
WO2021243122A8 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
KR20230018394A (ko) 조작된 코로나바이러스 스파이크(들) 단백질 및 이의 사용 방법
JP7660671B2 (ja) 融合前安定化ｈｍｐｖ ｆタンパク質
US20240317810A1 (en) Prefusion-stabilized chimeric hmpv-rsv f proteins
EP4580671A2 (en) Prefusion-stabilized cmv gb proteins
WO2022241229A1 (en) Stabilized s2 beta-coronavirus antigens
US12617820B2 (en) Engineered coronavirus spike (s) protein and methods of use thereof
US12616747B2 (en) Stabilized beta-coronavirus antigens
US20230277653A1 (en) Stabilized beta-coronavirus antigens
JP2026503061A (ja) 融合前安定化ヒトパラインフルエンザウイルス３ｆタンパク質
WO2025171082A1 (en) Prefusion-stabilized hsv2 gb proteins
WO2025212898A1 (en) Pre-fusion stabilized cchfv gp38-gn-gc glycoprotein complex
BR122024021506A2 (pt) Moléculas de ácido nucleico de proteína engenheirada compreendendo um ectodomínio de proteína f de metapneumovírus (mpv), e composiçao farmacêutica
BR122025014411A2 (pt) Molécula de ácido nucleico e composição farmacêutica que compreende a mesma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902